Prognostic value of androgen receptor expression in ER-positive/HER2-negative breast cancer: evidence from a contemporary Chinese cohort

Category	Detail
Condition	ER+/HER2− Luminal Breast Cancer
Key Mechanisms	Androgen receptor (AR) expression influences disease-free survival (DFS) and interacts with estrogen receptor (ER) signaling.
Target Population	Chinese patients with primary ER+/HER2− breast cancer
Care Setting	First Affiliated Hospital of Chongqing Medical University

Higher AR expression is associated with prolonged disease-free survival (DFS).
No significant association between AR expression and overall survival (OS) was observed.
AR expression may have prognostic value particularly in patients with residual disease after neoadjuvant chemotherapy.
Multivariable analysis identified AR expression as an independent factor for DFS.
Data from this study contributes to understanding AR's role in a contemporary Asian cohort.

Monitor DFS in relation to AR expression, especially in patients receiving neoadjuvant chemotherapy.

High AR expression may correlate with lower pathological complete response rates in neoadjuvant settings.

422 patients with primary ER+/HER2− breast cancer.

AR expression may influence treatment outcomes and should be considered in therapeutic decision-making.

Incorporate AR expression analysis in the evaluation of ER+/HER2− breast cancer.
Utilize AR expression data to inform prognosis and treatment strategies.

Clinical Scorecard: The Prognostic Importance of Androgen Receptor Expression in ER-Positive/HER2-Negative Breast Cancer: Insights from a Modern Chinese Patient Cohort